<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05102058</url>
  </required_header>
  <id_info>
    <org_study_id>2021/42</org_study_id>
    <nct_id>NCT05102058</nct_id>
  </id_info>
  <brief_title>Magnesium and Dexmedetomidine in Pheochromocytoma</brief_title>
  <official_title>Magnesium and Dexmedetomidine Combination Reduces Sodium Nitroprusside Requirement in Laparoscopic Pheochromocytoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anesthesia management of pheochromocytoma excision surgery is associated with severe&#xD;
      hemodynamic fluctuations.The objective of this study was to compare the hypertensive episodes&#xD;
      requiring sodium nitroprusside administration between the group treated with&#xD;
      magnesium-dexmedetomidine and conventional group in pheochromocytoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2011</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sodium nitroprusside (SNP) requirement</measure>
    <time_frame>intraoperative period</time_frame>
    <description>intraoperative hypertensive episodes requiring SNP therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>vasoactive therapy</measure>
    <time_frame>intraoperative period</time_frame>
    <description>hemodynamic fluctuations (hypotension, tachycardia, severe hypertensive crisis) which needed vasoactive therapy.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">108</enrollment>
  <condition>Phaeochromocytoma Crisis</condition>
  <condition>Hemodynamic Instability</condition>
  <arm_group>
    <arm_group_label>Conventional group (GC)</arm_group_label>
    <description>Not receive perioperative additional medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium-dexmedetomidine therapy group (GMD)</arm_group_label>
    <description>Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium-Dexmedetomidine</intervention_name>
    <description>Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively</description>
    <arm_group_label>Magnesium-dexmedetomidine therapy group (GMD)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients' data who were aged 18-75, had the American Society of Anesthesiologists&#xD;
        classification (ASA) 1-3 and high urinary catecholamine or metabolites. Patients with tumor&#xD;
        sizes &lt; 5 cm and body mass index (BMI) &lt;35 kg.m-2 were examined, who were evaluated&#xD;
        according to Endocrine Society Practice Guideline and provided the Roizen criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologists classification (ASA) 1-3&#xD;
&#xD;
          -  high urinary catecholamine or metabolites&#xD;
&#xD;
          -  tumor sizes &lt; 5 cm&#xD;
&#xD;
          -  body mass index (BMI) &lt;35 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  open surgery&#xD;
&#xD;
          -  bilateral masses&#xD;
&#xD;
          -  tumor larger than 5 cm&#xD;
&#xD;
          -  incomplete data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NÃ¼khet Sivrikoz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Attending anesthesiologist</affiliation>
  </overall_official>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University</investigator_affiliation>
    <investigator_full_name>Nukhet Sivrikoz</investigator_full_name>
    <investigator_title>Attending Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>Magnesium</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Nitroprusside</keyword>
  <keyword>Pheochromocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pheochromocytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

